Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of IMU-838 for Induction and Maintenance Therapy in Moderate-to-severe Ulcerative Colitis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Vidofludimus calcium (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms CALDOSE-1
- Sponsors Immunic
- 17 Oct 2023 Results of Efficacy and Safety of Vidofludimus Calcium (Imu-838) in Patients with Moderately to Severely Active Ulcerative Colitis , presented at the 31st United European Gastroenterology Week
- 16 Oct 2023 According to an Immunic media release, the company announced the presentation of data from this study in an oral prresentation at the United European Gastroenterology Week (UEGW) 2023, taking place October 14-17 in Copenhagen.
- 11 Oct 2023 This trial has been completed in Bulgaria (End Date: 16 Nov 2022), according to European Clinical Trials Database record.